NO20045038L - Kombinasjon av en beta-2 adrenoseptoragonist og et aminosukker og deres anvendelse ved behandling av immunomodulerende sykdommer - Google Patents

Kombinasjon av en beta-2 adrenoseptoragonist og et aminosukker og deres anvendelse ved behandling av immunomodulerende sykdommer

Info

Publication number
NO20045038L
NO20045038L NO20045038A NO20045038A NO20045038L NO 20045038 L NO20045038 L NO 20045038L NO 20045038 A NO20045038 A NO 20045038A NO 20045038 A NO20045038 A NO 20045038A NO 20045038 L NO20045038 L NO 20045038L
Authority
NO
Norway
Prior art keywords
beta
treatment
combination
adrenoceptor agonist
amino sugar
Prior art date
Application number
NO20045038A
Other languages
English (en)
Norwegian (no)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Publication of NO20045038L publication Critical patent/NO20045038L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
NO20045038A 2002-04-19 2004-11-19 Kombinasjon av en beta-2 adrenoseptoragonist og et aminosukker og deres anvendelse ved behandling av immunomodulerende sykdommer NO20045038L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37361502P 2002-04-19 2002-04-19
DKPA200200586 2002-04-19
PCT/DK2003/000263 WO2003097073A1 (fr) 2002-04-19 2003-04-22 Combinaison d'agonistes de recepteur adrenergique beta-2 et d'un sucre amine et leur utilisation pour le traitement de troubles immunomodulateurs

Publications (1)

Publication Number Publication Date
NO20045038L true NO20045038L (no) 2004-11-19

Family

ID=49447268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045038A NO20045038L (no) 2002-04-19 2004-11-19 Kombinasjon av en beta-2 adrenoseptoragonist og et aminosukker og deres anvendelse ved behandling av immunomodulerende sykdommer

Country Status (18)

Country Link
US (1) US20050130935A1 (fr)
EP (2) EP1496917B1 (fr)
JP (1) JP2005529151A (fr)
KR (1) KR20050007460A (fr)
CN (1) CN1646143A (fr)
AT (1) ATE311889T1 (fr)
AU (1) AU2003260279B2 (fr)
CA (1) CA2482746A1 (fr)
DE (1) DE60308915T2 (fr)
DK (1) DK1496917T3 (fr)
EA (1) EA007906B1 (fr)
ES (1) ES2254960T3 (fr)
HK (1) HK1073436A1 (fr)
NO (1) NO20045038L (fr)
NZ (1) NZ536447A (fr)
PL (1) PL373190A1 (fr)
SI (1) SI1496917T1 (fr)
WO (1) WO2003097073A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499170A1 (fr) 2002-09-27 2004-04-08 Children's Medical Center Corporation Procedes et compositions pour le traitement des troubles neurologiques
AU2005224160A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
DE602006015387D1 (de) 2005-04-13 2010-08-26 Astion Dev As Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
TW200800142A (en) * 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2013059629A1 (fr) 2011-10-21 2013-04-25 Nova Southeastern University Nanoparticules d'épinéphrine, leurs procédés de fabrication et leurs procédés d'utilisation pour le traitement d'états sensibles à l'épinéphrine
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
WO2007143676A2 (fr) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Posologies d'epinéphrine comprenant des formes pharmaceutiques buccales, linguales ou sublinguales
WO2007143675A2 (fr) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Procédés pour des posologies buccales, linguales ou sublinguales d'epinéphrine pour le traitement d'urgences allergiques
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
WO2008150477A2 (fr) * 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Mannosamine de n-acétyle en tant qu'agent thérapeutique
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
WO2010144865A2 (fr) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Procédés de traitement de troubles gastro-intestinaux
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US8716350B2 (en) 2010-03-30 2014-05-06 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
WO2011126910A2 (fr) 2010-03-30 2011-10-13 Algynomics Inc. Compositions et procédés pour le traitement de troubles somatosensoriels
CA3169368A1 (fr) 2012-06-15 2014-01-09 Nova Southeastern University Nanoparticules d'epinephrine, procede pour les fabriquer et procedes pour les utiliser pour le traitement d'affections repondant a l'epinephrine
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
DK2976072T3 (da) 2013-03-22 2021-08-16 Univ Nova Southeastern Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin
CN105601685B (zh) * 2016-01-08 2017-12-26 鲁东大学 含喹唑啉环壳寡糖衍生物及制备方法和生物活性
WO2018000098A1 (fr) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Traitement de myopathies inflammatoires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
JP3390477B2 (ja) * 1993-01-25 2003-03-24 生化学工業株式会社 薬剤組成物及びその製造法
WO1995019336A1 (fr) * 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Ethers de phenylethanolamine et leur utilisation comme agonistes des recepteurs adrenergiques beta
US6255295B1 (en) * 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
US6046179A (en) * 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
US20020136782A1 (en) * 2001-01-18 2002-09-26 Fleischner Albert M. Composition patent for solid-dosage form of weight loss product
US6420350B1 (en) * 2001-01-18 2002-07-16 Goen Group, Inc. Weight loss product

Also Published As

Publication number Publication date
DK1496917T3 (da) 2006-04-10
NZ536447A (en) 2006-05-26
EA007906B1 (ru) 2007-02-27
ATE311889T1 (de) 2005-12-15
AU2003260279A1 (en) 2003-12-02
EP1496917A1 (fr) 2005-01-19
KR20050007460A (ko) 2005-01-18
SI1496917T1 (sl) 2006-06-30
CN1646143A (zh) 2005-07-27
HK1073436A1 (en) 2005-10-07
DE60308915T2 (de) 2006-12-21
DE60308915D1 (de) 2006-11-16
ES2254960T3 (es) 2006-06-16
EP1642574A2 (fr) 2006-04-05
EA200401404A1 (ru) 2005-04-28
PL373190A1 (en) 2005-08-22
JP2005529151A (ja) 2005-09-29
US20050130935A1 (en) 2005-06-16
EP1642574A3 (fr) 2008-11-12
EP1496917B1 (fr) 2005-12-07
CA2482746A1 (fr) 2003-11-27
AU2003260279B2 (en) 2008-01-24
WO2003097073A1 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
NO20045038L (no) Kombinasjon av en beta-2 adrenoseptoragonist og et aminosukker og deres anvendelse ved behandling av immunomodulerende sykdommer
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
RU2008103480A (ru) Средство, содержащее l-карнитин или производные l-карнитина и, по меньшей мере, одно определенное другое вещество
TW200637488A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
NO20050718L (no) Topikal behandling av hudsykdommer
AU2003249356A1 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
DE60237431D1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
DE59509751D1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
WO2005023185A3 (fr) Compositions pharmaceutiques et procede d'utilisation de la levodopa et de la carbidopa
WO2000035475A3 (fr) Methode de traitement des ischemies cerebrales et utilisation de l'erythropoietine ou de derives de l'erythropoietine pour traiter les ischemies cerebrales
NO20055136L (no) Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer
WO2006108424A3 (fr) Traitement de maladies du tissu conjonctif cutane
DE60124715D1 (de) Er produktion von beta-endorphin
WO2004082630A3 (fr) Traitement dopaminergique tres puissant de deficiences neurologiques associees a des lesions du cerveau
AU2003304410A1 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
WO2004080284A3 (fr) Therapie photodynamique ciblee sur les anticorps
EP1157698A3 (fr) Traitement des maladies inflammatoires avec des nucleosides a base d'oxypurine
WO2004014367A3 (fr) Immunisation anti-amyloide et inhibiteurs de cox-2 utilises dans le traitement de la maladie d'alzheimer
WO2006047470A3 (fr) Compositions contenant un extrait de malva sylvestris et utilisation de ces compositions sur des tissus muqueux
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
PT1572178E (pt) Tratamento de mastalgia com 4-hidroxi-tamoxifeno
WO2009106555A3 (fr) Gel de sucralfate sterilise
WO2003092645A3 (fr) Composition cosmetique comprenant des mono- ou poly-saccharides
EP1546377A4 (fr) Methodes et compositions de traitement de la douleur et des troubles douloureux a l'aide des molecules 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 ou 13424

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application